Actual NuvaRing shown


About NuvaRing

NuvaRing is a combination contraceptive vaginal ring containing two active components: a progestin (etonogestrel) and an estrogen (ethinyl estradiol).

When used as directed, NuvaRing is just as effective as the Pill. In a given one-month period, NuvaRing must be inserted vaginally, removed after 3 weeks, and a new ring must be inserted 7 days later.

What's more, a clinical study found that many women say that NuvaRing is easy to use. In this randomized, open-label trial (which compared NuvaRing users with users of a combined oral contraceptive), 95% of women who used NuvaRing and completed the study (N=355) reported that the ring was easy to insert and remove.1,2

  1. Dieben TOM, Roumen FJME, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002; 100(3): 585-593.
  2. Data available on request from Merck, Professional Services-DAP, WPI-27, PO Box 4, West Point, PA 19486-0004. Please specify information package WOMN-1032072-0000.
  3. Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Investig. 2010;30(11):749-763.
  4. Thompson MM. Women’s attitudes, perceptions, and knowledge about the vagina. Sex Reprod Menopause. 2006;4(2): 74-79.

NuvaRing is indicated for the prevention of pregnancy in women.

Selected Safety Information

Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination hormonal contraceptives, including NuvaRing, should be strongly advised not to smoke.
  • The use of combination oral contraceptives is associated with increased risks of several serious side effects, including stroke and heart attack. NuvaRing is not for women with a history of these conditions. Combination oral contraceptives are also associated with increased risk of thromboembolic diseases. Some studies suggest that this risk is increased by combination oral contraceptives containing desogestrel; additional studies do not support this finding. It is unknown whether NuvaRing has a different risk of venous thromboembolism (VTE) than that of second-generation oral contraceptives.
  • NuvaRing is not for women with certain cancers or those who may be pregnant.
  • NuvaRing does not protect against HIV infection or other sexually transmitted diseases.
  • The most common adverse events reported by 5% to 14% of women using NuvaRing in clinical trials (N=2,501) were vaginitis, headache, upper respiratory tract infection, vaginal secretion, sinusitis, weight gain and nausea.

Before prescribing NuvaRing, please read the Prescribing Information, including the Boxed Warning about the increased risk of serious cardiovascular side effects, especially in women who smoke.